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Background: Knowledge is limited regarding the association between stem cells in histologically benign breast
tissue and risk factors for breast cancer, and hence we addressed this issue in the present study. Recently, we assessed
the histology of benign breast tissue from cancer and non-cancer patients for cells positive for the putative stem cell
marker aldehyde dehydrogenase 1 A1 (ALDH), and the findings indicated an association between expression of ALDH
and the hormonal factors menopause and hormone therapy. The current investigation examined possible associations
between various known clinical and genetic risk factors for breast cancer and cellular expression of ALDH in ductules in
benign human breast tissue.
Methods: The study included breast surgery patients that were BRCA1/2 mutation carriers without breast cancer (n = 23),
had BRCA1/2 (n = 28) or sporadic (n = 21) breast cancer, or required non-cancer-related mammoplasty (n = 34). The
distribution and frequency of ALDH-immunolabelled cells were correlated to patient subgroups with different risk
factors, using mammoplasty patients as a control group. Statistical analyses comprised linear and logistic regression,
Spearman’s rank test, Pearson’s test, and Fisher’s exact test. In two-tailed tests, p < 0.05 was considered significant.
Results: A strong association was found between family history of breast cancer and a high frequency of ALDH+ cells
(p = 0.001) at all ductular levels in all groups, regardless of BRCA status, age, parity, or occurrence of cancer. In pre-
menopausal non-BRCA cancer patients, the frequency of ALDH+ cells increased with age (p < 0.01) but decreased with
increasing parity (p < 0.03). High frequencies of ALDH+ cells were found in the non-basal ductular levels in BRCA1
mutation carriers (p = 0.03), but in the basal ductular level in BRCA2 cancer patients (p = 0.02). Among post-menopausal
patients, only on-going hormone replacement therapy was correlated with a high number of ALDH+ cells (p < 0.03).
Conclusion: In histologically normal breast tissue, we found a positive association between the frequency of ductular
ALDH+ cells and several breast cancer risk factors, particularly family history of this disease, which supports previous
evidence that ALDH plays a role in breast cancer.
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A stem-like cancer cell is defined as a cell with the cap-
acity for self-renewal and the ability to generate different
cell types that form a tumor [1]. In 2003, the presence of
benign stem cells in non-histological breast tissue prepa-
rations was identified on the basis of functional cell
characteristics [2,3], and a brief histological description
of these cells was published in 2007 [4]. It has been pro-
posed that aldehyde-dehydrogenase-expressing (ALDH+)
breast cells include malignant stem-like cell populations
that maintain and cause progression of cancer [4,5].
ALDH catalyzes oxidation and is necessary for retinoic
acid synthesis, and it has been suggested that this enzyme
is also involved in stem cell preservation and initiation of
differentiation [6]. Normal mammary stem cells and stem-
like cancer cells were recently shown to express an alter-
native isoform of ALDH [7], but the stem cell properties
or cancer-related functions of cells that are positive for
any isoform still remain unclear.
Several clinical and molecular factors predict the risk
of developing breast cancer. For example, the presence
of BRCA1 and BRCA2 gene mutations confers a 40–80%
lifetime risk [8], and exogenous hormone exposure is as-
sociated with relative risks of 1.5 to 2.0 [9]. Furthermore,
non-malignant histological changes such as atypical
ductal hyperplasia are associated with a 28% risk of breast
cancer [10].
ALDH+ cells are found in up to 48% of breast cancer
tumors and are believed to cause late recurrence, and
these cells are also associated with an adverse prognosis
and poor outcome after conventional anti-cancer drug
treatment [5,11,12].
To assess the potential of ALDH as a predictive
marker for subsequent development of breast cancer, it
is necessary to define the normal ranges of frequencies
and distribution of ALDH+ cells in histologically benign
breast tissue in women with and without breast cancer.
Such data are limited at present, although a small case-
control study showed elevated levels of ALDH+ cells in
epithelium and stroma of patients who later developed
cancer [13], and an investigation of African women re-
vealed a higher frequency of ALDH+ cells in breast can-
cer tissue compared to benign breast tissue [14]. It is
also essential to determine whether the frequency or dis-
tribution of ALDH+ putative stem cells in histologically
normal breast tissue is related to risk factors for breast
cancer. We recently described in detail the distribution
of ALDH+ cells in terminal duct lobular units (TDLUs)
and stroma in benign breast tissues [15]. The correla-
tions with risk factors that were observed in the small
group of patients assessed in that investigation suggested
that density and distribution of ALDH+ cells are associ-
ated with menopausal state and hormone replacement
therapy. Therefore, our aim in the present study was toexamine ALDH expression in ductular cells in a larger pa-
tient group and to elucidate the relationship between such
expression and various risk factors for breast cancer, in-
cluding BRCA1/2 mutation status, familial breast cancer
history, hormone intake, parity, and age at menarche.
Methods
Patient material
The patients considered for inclusion in this study were
female patients who had been treated with breast sur-
gery in Skåne County and met the criteria for one of the
following groups:
Group A (n = 30): breast cancer patients without BRCA1/
2 mutation; surgery during the period 1999–2006.
Group B (n = 19): breast cancer patients with BRCA1
mutation; surgery during the period 1984–2009.
Group C (n = 16): breast cancer patients with BRCA2
mutation; surgery during the period 1984–2009.
Group D (n = 13): BRCA1 mutation carriers without
breast cancer; prophylactic mastectomy during the
period 1996–2010.
Group E (n = 13): BRCA2 mutation carriers without
breast cancer; prophylactic mastectomy during the
period 1996–2010.
Group F (n = 35): patients without breast cancer or
BRCA1/2 mutations; mammoplasty during the period
1993–1994.
Thus a total of 126 patients were reviewed for inclusion
in our study. An experienced histopathologist (BLI) exam-
ined the original hematoxylin and eosin (H&E) stained
microscope slides from each patient without knowledge of
the clinical parameters. The tissue blocks containing the
largest number of histologically normal TDLUs for each
patient were selected for the investigation. Exclusion
criteria were any of the following: patient received neoad-
juvant therapy; no tissue blocks available in the archives;
no tissue block contained ≥10 morphologically benign
TDLUs. Based on the mentioned criteria, a total of 106
patients were included in the study (see Table 1).
Data on the following clinical parameters were avail-
able for the majority of the patients: indication for sur-
gery, age at time of surgery, current or previous use and
total duration of use of oral contraceptives and or hor-
mone replacement therapy (HRT), age at menarche,
number of live childbirths (parity), family history of
breast cancer (1st or 2nd degree relative), and BRCA1/2
mutation status. Table 1 presents information on the
age, hormonal exposure, and reproductive status of the
women included in the study.
Sixty-seven of the women were pre-menopausal, 35
were post-menopausal, and data were missing for four.
The median age at onset of menopause was 49 years

















A Cancer, non-BRCA1/2 21 50 (31–77) 4 NA NA 8 4 9 0 3 1 0
B Cancer, BRCA1 17 43 (23–81) 17 17 NA 4 10 0 3 4 1 3
C Cancer, BRCA2 11 51 (33–74) 11 NA 11 0 7 3 1 0 1 2
D Prophylactic mastectomy,
BRCA1
12 37 (23–54) 12 12 NA 0 6 4 1 0 4 1
E Prophylactic mastectomy,
BRCA2
11 37 (31–51) 11 NA 11 0 5 5 1 0 0 1
F Mammoplasty, non-cancer,
non-BRCA
34 31 (20–68) 5 NA NA 19 7 8 0 0 8 1
Patient groups included in the study and subsequently re-grouped according to the listed parameters for analysis of ALDH+ cells. The table presents selected clinical,
genetic, and hormonal characteristics of patients.
NA, not applicable; HRT, hormone replacement therapy; OC, oral contraceptive.
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the women were as follows: para 0 in 32, para 1 in 11,
para 2 in 28, para 3 in 25, and para 4 in four. The me-
dian age at menarche was 13 years (range, 10–18 years;
data missing for 32 women). Data regarding exogenous
hormone treatment status at the time of surgery were as
follows: 70 women had no such treatment, 15 used oral
contraceptives, seven received HRT, and six had a pro-
gestin intrauterine device. Sixty-five women had used
oral contraceptives at sometime during their lives (me-
dian duration, 7.1 years), and 11 had received HRT at
some point (median duration, 5.0 years). Clinical data
and breast tissue samples representing 25 of the 28 pa-
tients in our previous study [15] were included in the
present analysis.
Histology and immunohistochemistry
If two tissue blocks from the same patient were of similar
superior quality, both (from the same or both breasts)
were analyzed in the same manner for quality assurance
purposes. New sections were obtained from all relevant
paraffin tissue blocks, and consecutive sections were H&E
stained and used for immunohistochemistry, as described
previously in detail [15]. Briefly, after antigen retrieval, the
sections were incubated with mouse monoclonal anti-
bodies directed against human ALDH1 A1 (aa 7–128, N-
term, diluted 1:100; Becton, Dickinson and Company,
Franklin Lakes, NJ, USA). Detection of immunoreactive
sites was performed using a system based on horseradish
peroxidase (HRP) and di-aminobenzidine (DAPI) labelling
of primary antibodies raised in mice (Envision+ System-
HRP, Dako, Glostrup, Denmark). Sequential incubations
were performed with secondary antibodies and HRP-
conjugated antibodies. Following the peroxidase reaction
in DAPI and H2O2, the sections were rinsed and counter-
stained with hematoxylin, and then dehydrated and cover-
slipped in Mountex medium (Histolab Products AB,Göteborg, Sweden). To confirm the specificity of ALDH
labelling, slides that were not incubated with the primary
antibodies were included in each immunohistochemistry
run.
The tissue sections selected for ALDH immunolabel-
ing were assessed regarding the following features: tissue
fragment size, epithelial atypia or hyperplasia, invasive
carcinoma, and total number of TDLUs. The tissue areas
available in each chosen block ranged in size from 48 to
621 mm2with a median value of 254 mm2. Areas dis-
playing ductular or lobular hyperplasia, atypia, carcin-
oma in situ (four cases), or invasive carcinoma (10
cases) were excluded from further analysis. To evaluate
the distribution and number of immunolabelled ALDH+
cells, 50 TDLUs were examined, guided by a grid, at
evenly spaced intervals in each tissue section; if fewer
than 50 TDLUs were present in a section, all the TDLUs
were evaluated. The number of TDLUs found to be avail-
able for analysis of ALDH immunoreactivity in each pa-
tient ranged from 13 to 50 (mean, 45 TDLUs). Only
ductules (i.e., no ducts or stroma) were evaluated. In our
previous study [15], we described ALDH+ cells as being in
a basal, luminal, or intermediate location. For each patient
in the present study, the number of TDLU cross sections
with ductular ALDH+ cells was recorded for each duct-
ular level (luminal, intermediate, or basal) in relation to
the total number of TDLU cross sections examined.
ALDH immunoreactive cells that were labelled either
strongly or weakly were considered to be positive for
ALDH. Furthermore, cells found in luminal and inter-
mediate ductular locations were defined as non-basal
(luminal plus intermediate) in some analyses, as indi-
cated in the text. This was done because determination
of cell location by ductular level is less accurate when
ductules lack microscopically discernible lumina.
Blind testing of ALDH+ cell frequency in duplicate
tissue samples from 13 patients yielded correlation
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cating similarity between independent observations (rs =
0.65, p = 0.01). These results confirmed the robustness of
the analysis and demonstrated similarity between different
areas of breast tissue in the same patient.
Statistical analysis
The number of TDLUs with detectable ALDH+ cells and
basal and non-basal localization of those cells were ana-
lyzed by linear regression using occurrence of ALDH+
cells in the mammoplasty group as the independent vari-
able. Logistic regression was used to analyze differences
between risk factor groups. Correlation between ALDH
findings for duplicate samples from the same patient was
analyzed using Spearman’s rank test and Pearson’s test.
Two-tailed tests were performed to assess the level of stat-
istical significance, and results with p < 0.05 were consid-
ered significant. SPSS 18 software (IBM, Armonk, NY,
USA) was used for all statistical analyses.
Ethics
The study was approved by the Research Ethics Committee
for Southern Sweden (approval 11-92, 349-00).
Results and discussion
Division of patient inclusion groups A–F into
analysis groups
Patients in inclusion groups A–F were divided into rele-
vant groups on the basis of genetic and hormonal status
to enable various analyses of ALDH+ cells.
Distribution of ALDH+ cells
ALDH+ cells were detected in TDLUs of 92 patients
(87%), including the youngest (aged 20 years) and the old-
est (aged 81 years). ALDH+ cells in ductules were morpho-
logically similar to other ductular epithelial cells (Figure 1),
and they were observed either as a few scattered cells or or-
ganized in groups comprising partial or entire ductular
cross sections. The ALDH+ cells occurred primarily in the
adluminal and intermediate levels (Figure 1B), and in some
cases they were found in the adluminal level only
(Figure 1C), or less often in all levels (Figure 1A). In several
cases, ALDH+ cells extended across a ductular lumen, in-
dicating the luminal aspect of a bifurcation. ALDH+ cells
were located adluminally in 0–74% of TDLUs (median 6%),
intermediately in 0–68% (median 6%), and basally in 0–
30% (median 2%), thus implying predominantly non-basal
localization of ALDH+ cells, as reported previously [4,15].
ALDH+ cells in the six patient groups
ALDH+ cells were present in the epithelium at some duct-
ular level in 90% of the subjects (19/21) in Group A
(breast carcinoma with no BRCA mutations) and in a
similar fraction (94%, 16/17) of the patients in Group B(breast carcinoma with BRCA1 mutation), but in a smaller
fraction (73%, 8/11) of those in Group C (breast carcin-
oma with BRCA2 mutation). Also, ALDH+ ductular cells
were detected in 100% (12/12) of the patients in group D
(prophylactic mastectomy due to a BRCA1 mutation)
and 100% (11/11) of those in Group E (prophylactic
mastectomy due to a BRCA2 mutation). In Group F
(mammoplasty patients with neither cancer nor BRCA1/
2 mutations), ALDH+ ductular cells were found in 76%
(26/34) of the patients.
There was no statistically significant difference in the
frequency of ALDH+ cells among the patient groups
(p = 0.09), although a higher frequency was noted for
patient Groups A–E combined compared to the mam-
moplasty group (p = 0.06, Fisher’s exact test). This
finding, together with previous evidence that ALDH+
cells in different levels of the ductular epithelium are
differentially associated with risk factors for breast cancer,
[15] prompted a detailed analysis of patient subgroups
regarding the occurrence of ALDH+ cells in the various
levels of the ductular epithelium (see below).
ALDH+ cells in patients with a family history of breast
cancer but no BRCA1/2 mutations
Pre-menopausal patients with a family history of breast
cancer but no BRCA1/2 mutations were significantly asso-
ciated with large numbers of ALDH+ cells at all ductular
levels (p ≤ 0.01; Figure 2A). This association was inde-
pendent of parity, age, and personal history of cancer,
which indicates a positive relationship between ALDH ex-
pression and familial risk of breast cancer in women with-
out BRCA1/2 mutations. Notably, such an association
with high frequency of ALDH+ cells was not observed at
any ductular level in post-menopausal patients. Further
information on these results is given in Table 2.
ALDH+ cells in patients with a BRCA1 or BRCA2 mutation
Compared to breast tissue from mammoplasty patients,
such tissue from pre-menopausal women who underwent
preventive mastectomy due to BRCA1 carrier status con-
tained significantly larger numbers of ALDH+ cells at
non-basal ductular levels (p = 0.03; see Figure 2B). A posi-
tive association of borderline significance (p = 0.06) was
noted for ALDH+ cells located at the basal ductular level
in the BRCA1 mutation carriers. No difference in the oc-
currence or distribution of ALDH+ cells in breast tissue
was observed between women with breast cancer and
BRCA1 gene mutations and those who underwent mam-
moplasty. Larger numbers of ALDH+ cells at non-basal
ductular levels were discerned in tissue from pre-
menopausal women with breast cancer and BRCA2 gene
mutations than in tissue from mammoplasty patients
(p = 0.02; Figure 2C). The post-menopausal BRCA1 and
BRCA2 patient subgroups showed no significant
Figure 1 Distribution of ALDH+ cells in benign breast ductules. Brown staining indicates ALDH immunoreactivity. A, ALDH+ cell populations
(arrows) located at luminal, basal, and intermediate ductular levels (levels described in detail elsewhere [15]). B, Micrograph showing an ALDH+ cell
population (arrow) and ALDH+ stromal cells (arrowhead; as previously described [15]). C, Some ALDH+ cells are locatedin ductular bifurcations (arrow;
cell type described previously [4,15]). All sections were counterstained with hematoxylin; scale bars in all three micrographs represent 50 μm.
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Table 2 gives further information regarding these results.
It should also be mentioned that a higher frequency of
ALDH+ cells in ductules was found in patients with
BRCA1 mutations than in those with BRCA2 mutations.
This may reflect the dissimilarities in oncogenesis be-
tween different types of BRCA mutations that have been
described by other investigators [16].Figure 2 Frequency of ALDH+ cells in ductules of benign breast tissu
cancer. ALDH+ cells were detected significantly more often in tissue from pa
ALDH+ cell populations (arrows) in breast tissue from a woman with a family
periphery of blood vessels, such as in the large Y-shaped structure in the cen
this study). B, Image demonstrating ALDH+ cell populations (arrows) in benig
ALDH+ cell populations (arrows) in benign breast tissue from a woman withALDH+ cells in relation to age and menarche
Among pre-menopausal patients without BRCA muta-
tions, age was positively associated with the frequency of
ALDH+ cells at all ductular levels (p ≤ 0.01; Figure 3),
even after adjusting for parity and family history of
breast cancer (p = 0.01), which suggests that risk factors
have a stronger influence with increasing age. This associ-
ation was not found within the post-menopausal group.e from pre-menopausal women with a family history of breast
tients in this group than in control patients. A, Representative image of
history of breast cancer but no BRCA1/2 mutation. ALDH+ cells in the
ter of this image, were detected in some cases (not analyzed further in
n breast tissue from a woman with a BRCA1 mutation. C, Image showing
a BRCA2 mutation. Scale bar in A represents 100 μm in all three images.
Table 2 Immunohistochemistry results








Pre-menopausal with family history of breast cancer, including patients with BRCA1
or BRCA2 mutation (n = 37)
12 (0–62)** 12 (0–53)** 2 (0–18)
Pre-menopausal with BRCA1 mutation (n = 18) 15 (2–50)* 15 (6–38)* 4 (0–18)
Pre-menopausal with BRCA2 mutation (n = 13) 14 (0–62)* 8 (2–53)* 0 (0–18)
Pre-menopausal without family history of breast cancer (n = 25) 6 (0–29) 6 (0–44) 0 (0–29)
Post-menopausal receiving HRT at the time of surgery (n = 7) 10 (0–38)* 8 (0–38)* 2 (0–21)
Post-menopausal not receiving HRT at the time of surgery (n = 24) 4 (0–32) 4 (0–34) 0 (0–18)
Nocancer, underwent mammoplasty (n = 34) 6 (0–32) 4 (0–44) 0 (0–29)
A statistical comparison of ALDH immunohistochemistry results for patients with and without a family history of breast cancer, and patients who were or were not
receiving HRT at the time of surgery.
*P ≤ 0.05.
**P ≤ 0.01.
ALDH, aldehyde dehydrogenase 1 A1; TDLU, terminal duct lobular unit; HRT, hormone replacement therapy.
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the distribution of ALDH+ cells.
ALDH+ cells in relation to parity
In breast tissue from pre-menopausal patients with or
without cancer or BRCA mutations, adjusted for age, the
frequency of ALDH+ cells at all three ductular levels was
significantly lower with increased parity (p ≤ 0.03; see
Figure 4). This relationship was not observed in the post-
menopausal group. Thus the lower risk of breast cancer
associated with higher parity [17] may be related to the
lower frequency of ALDH+ cells in high-parity patients.
However, this possibility needs to be further investigated
using a larger data set and focusing on mutation status.
ALDH+ cells in relation to HRT and oral contraceptives
No correlation was found between the use of oral con-
traceptives at the time of surgery and the frequency of
ALDH+ cells at any ductular level in breast tissue, indi-
cating that the hormonal impact of oral contraceptives
alone is not sufficient to override physiological hormonalFigure 3 Frequency of ALDH+ cells in benign ductules of pre-menopa
ductules in breast tissue from a 31-year-old patient (A) and from a and a 5
ALDH+ cells (arrows) with increasing age. Scale bar in A represents 100 μmchanges. However, compared to post-menopausal women
who were not using HRT at the time of surgery, those
who were on such therapy had larger numbers of ALDH+
cells in tissue at basal (p = 0.025) and non-basal (p = 0.03)
levels (Figure 5 and Table 2), and this difference was inde-
pendent of other risk factors. In the post-menopausal
group, HRT was the only hormone intake parameter that
showed a statistically significant correlation with a high
frequency of ALDH+ cells, which agrees with evidence
that HRT postpones TDLU involution and increases the
risk of cancer [18-21]. This finding also suggests that on-
going HRT may be one of the factors that influence the
number of ALDH+ cells.
In contrast, neither the total duration of contraceptive
pill usage nor the duration of HRT was associated with
the frequency of ALDH+ cells, which suggests that ex-
ogenous hormones have only a transient effect on the oc-
currence of ALDH+ cells in benign breast tissue, and is
consistent with previously reported data on sex hormone
therapies suggesting that ongoing or recent intake of HRT
increases the risk of breast cancer [19].usal women of different ages. Representative images of benign
0-year-old patient (B) demonstrating significantly higher frequency of
in both images.
Figure 4 Frequency of ALDH+ cells in benign ductules of pre-menopausal women with different parities. Representative images of benign
ductules in pre-menopausal patients demonstrate a significant decrease in frequency of ALDH+ cells (brown) with increasing parity in this patient sub-
group. A, Image illustrating the relatively large number of ductular ALDH+ cells (arrows) in breast tissue from a 39-year-oldnulliparous woman. B, Image
of breast tissue from a 38-year-old two-parous woman showing therelatively small number of TDLUs containing ductular ALDH+ cells (arrow), and
scattered ALDH+ cells in the stroma. C, Image revealing the lack of ductular ALDH+ cells in breast tissue from a 41-year-old four-parous woman. Scale
bars: 100 μm.
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The present findings support the hypothesis that ALDH
+ breast cell populations participate in oncogenesis. We
found several associations between high frequencies of
ALDH+ cells in benign breast tissue and clinical riskFigure 5 Frequency of ALDH+ cells in benign ductules of post-menop
Representative images of tissue from post-menopausal women are present
cells in breast tissue from women receiving HRT treatment at the time of s
taining ALDH+ cells (arrows) in benign breast tissue from a 70-year-old wo
breast tissue from a 74-year-old woman who was not receiving HRT at the
absence of ALDH+ cells (white arrows indicate ductules with no ALDH+ ce
cells, as demonstrated in all patient groups. Scale bars: 100 μm.factors for cancer. Also, statistical analysis of subgroups
demonstrated significant correlations between ALDH+
cells and family history of breast cancer, parity, and HRT
exposure (see Table 2). Larger studies are needed to as-
sess other risk factors for breast cancer in this context.ausal women with and without HRT at the time of surgery.
ed that demonstrate the significantly increased frequency of ALDH+
urgery. A, Image illustrating the relatively high number of TDLUs con-
man receiving HRT at the time of cancer surgery. B, Image of benign
time of surgery, showing the presence of relatively few or complete
lls). The benign tissue from this woman also contained ALDH+ stromal
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The patients evaluated in the present study were treated
between 1984 and 2010, and the surgical techniques and
oncological treatment protocols being applied during
that period were subject to changes. However, the poten-
tial impact of those modifications on the results of our
investigation can be assumed to be negligible for the fol-
lowing reasons: (1) patients who received neoadjuvant
therapy were excluded; (2) possible influence of variation
in antigenicity related to heterogeneous tissue fixation
was reduced to a minimum by using ALDH positivity in
stromal cells as internal control, and by considering all
cells exhibiting weak or strong immunoreactivity as
positive for expression of ALDH.
Our study demonstrated associations between ALDH+
cell frequencies in benign breast tissue and risk factors
for breast cancer, but we found no significant relation-
ship between ALDH+ cell frequencies in benign tissue
and the co-presence of cancer. This finding might be ex-
plained by the influence of temporal and spatial factors
of a developing cancer; more specifically, that the cancer
is established after the occurrence of a risk factor, and
the tumor can overgrow ALDH+ cells.
In our previous study conducted using the same
methods [15], a higher frequency of ALDH+ ductular
cells was found in mammoplasty patients than in pa-
tients with established breast cancer. In contrast, in the
present investigation, data on mammoplasty patients
were used to allow comparison of non-breast cancer and
breast cancer patients, the latter group including many
individuals with a familial risk of breast cancer. How-
ever, inasmuch as increased cell mass in a breast predis-
poses to cancer [22,23], it would be most suitable to
obtain control tissue from patients without breast dis-
ease, not from those with breast hyperplasia.
Conclusion
The present study demonstrated a positive association
between the frequency of ALDH+ ductular cells in be-
nign female breast tissue and several well-known risk
factors for breast cancer. These findings suggest that
ALDH cell positivity in microscopically normal breast
tissue should be further evaluated as a potential marker
for the risk of breast cancer, especially in patients with fa-
milial breast cancer with or without BRCA1/2 mutations.
The largest differences in ALDH+ cell frequency be-
tween risk groups were observed in the luminal and
intermediate (non-basal) ductular locations. Our data in-
dicate that ALDH-expressing cells may play a yet un-
defined role in the development of female breast cancer,
and they also suggest that immunohistochemical analysis
of ALDH can aid prediction of the risk of breast cancer.
It is conceivable that having a high number of ALDH+
stem cells promotes a high number of progenitor cells,and that the latter are susceptible to oncogenesis. The
current results underline the need for further research
to assess the previously proposed stem and/or progeni-
tor qualities of ALDH+ cells in normal breast tissue and
their potential role in carcinogenesis.
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